Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Also in the first quarter, we entered into a broad manufacturing agreement with CordenPharma to support the future commercialization of VK2735. This comprehensive agreement provides access to ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

Viking continued to build on the strong momentum achieved in 2024,” stated Brian Lian, Ph.D., chief executive officer of Viking. “Throughout the first quarter we continued to ramp up activities in ...

Also in the first quarter, we entered into a broad manufacturing agreement with CordenPharma to support the future commercialization of VK2735. This comprehensive agreement provides access to ...

SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ: VKTX) reported a wider-than-expected loss for the first quarter of 2025 as research and development expenses increased, but its stock edged up 1% ...

The company completed the enrollment for its Phase 2 trial of VK2735, a dual agonist targeting obesity, and entered a significant manufacturing agreement with CordenPharma, focusing on securing ...